# THIO Sequenced With Cemiplimab in Advanced NSCLC

Source: https://onco.cc/trials/nct05208944/  
OnCo record `nct05208944` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Cemiplimab in non-small-cell lung cancer, run by Maia Biotechnology, active and no longer recruiting.

## Summary

THIO Sequenced With Cemiplimab in Advanced NSCLC is a phase 2 interventional study registered as NCT05208944 by Maia Biotechnology, with 227 participants enrolled, started 2022-06-08 and due to reach its primary completion in 2027-09-30. Interventions recorded: 6-Thio-2'-Deoxyguanosine and Cemiplimab.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05208944
- Phase: 2
- Setting: A Multicenter, Open-Label, Dose-Finding, Phase 2 Study Evaluating THIO Sequenced With Cemiplimab (LIBTAYO®) in Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC)
- Sponsor: Maia Biotechnology
- Enrolled: 227

## Sources

- ClinicalTrials.gov NCT05208944: https://clinicaltrials.gov/study/NCT05208944

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Cemiplimab](https://onco.cc/drugs/cemiplimab/)
- companies: [Maia Biotechnology](https://onco.cc/companies/maia-biotechnology/)

---
JSON: https://onco.cc/api/v1/entities/nct05208944.json